Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1054 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

MJFF awards research grant to Melior

The grant will enable Melior to test the usage of a drug currently used in other disease areas for its effects in preclinical models of Parkinson’s disease. MJFF

Lotus Pharma Q2 revenues up

The company has posted a net income of $1.77m for the second quarter of 2011, compared to $6.32m for the same period in 2010. Lotus’ income from operations

Aegis peptide analogs receive US patent

GLP-1 peptide analogs are suitable for all routes of administration including the non-invasive oral or metered nasal spray delivery routes or injection. Aegis’ patented drug delivery and drug

BAC in pact with BMS

Adnectins are designed by using BMS‘ proprietary PROfusion technology to either block or stimulate the action of specific targets across a range of therapeutic areas. Under the agreement,

Biosceptre gets AU$8m to develop NMSC drug

The active ingredient in BSCT topical treatment is a polyclonal antibody directed towards Biosceptre’s novel proprietary cancer target, nf-P2X7. Biosceptre expects to start clinical studies for BSCT at

NIAID to start Phase 1 trial with Destiny Pharma drug

XF-73, a novel dicationic porphyrin, is under development for the prevention of post-surgical Staphylococcal infections. The Phase 1 trial aims to evaluate the safety, tolerability and preliminary anti-Staphylococcal